3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
52
Breast Neoplasms
24
Lung Neoplasms
21
Triple Negative Breast Neoplasms
16
Neoplasm Metastasis
16
Pancreatic Neoplasms
15
Neoplasms
15
Colorectal Neoplasms
14
Stomach Neoplasms
13
Head and Neck Neoplasms
12
Esophageal Neoplasms
12
Esophageal Squamous Cell Carcinoma
11
Uterine Cervical Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Small Cell Lung Carcinoma
9
Rectal Neoplasms
8
Ovarian Neoplasms
8
Leukemia, Myeloid, Acute
8
Recurrence
7
Nasopharyngeal Carcinoma
7
Glioblastoma
5
Fallopian Tube Neoplasms
5
Cholangiocarcinoma
5
Urinary Bladder Neoplasms
4
Sarcoma
4
Oropharyngeal Neoplasms
4
Mouth Neoplasms
4
Lymphoma
4
Endometrial Neoplasms
4
Colonic Neoplasms
4
Interventions
Cyclophosphamide
47
Rituximab
31
fludarabine
29
Specimen Handling
13
Magnetic Resonance Spectroscopy
13
Doxorubicin
13
pirtobrutinib
11
Vincristine
11
Prednisone
11
fludarabine phosphate
10
Immunotherapy, Adoptive
10
Etoposide
10
Bendamustine Hydrochloride
10
obinutuzumab
8
Lenalidomide
8
Biopsy
8
venetoclax
7
polatuzumab vedotin
7
glofitamab
7
zanubrutinib
6
pembrolizumab
6
Dexamethasone
6
tafasitamab
5
ibrutinib
5
etoposide phosphate
5
acalabrutinib
5
Leukapheresis
5
tazemetostat
4
loncastuximab tesirine
4
Nivolumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Drug Therapy
×
1 year
×
Clear all
NCT03570892
2026-05-14
BELINDA
Novartis
Phase 3
Completed
330 enrolled
10 charts